The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an urgent warning for anyone using Milpharm‑branded loperamide hydrochloride 2 mg tablets, commonly sold as Imodium Instants. The agency discovered that patient information leflets in batches 25882X3 and 25882X2 give incorrect directions on how to take the dissolvable tablets, prompting a rapid public health advisory.

Mislabelled medication can turn a routine over‑the‑counter remedy into a safety risk, especially when the error involves the method of administration. As the MHRA explained, the affected leaflets advise swallowing the tablets with water, whereas the correct practice is to let them dissolve on the tongue. This distinction matters because improper ingestion can increase the chance of a rare burniing sensation in the mouth and may affect how quickly the drug acts, potentially leading to under‑ or over‑treatment of diarrhoea.

Beyond the immediate health concern, the incident highlights ongoing challenges in pharmaceutical supply‑chain oversight in the UK. Similar packaging mishaps have previously forced regulators to recall products ranging from antihistamines to antibiotics,underscoring the need for tighter quality‑control checks. For consumers, the alert serves as a reminder to verify that the accompanying leaflet matches the product’s intended use, especially for fast‑acting formulations that deviate from standard swallow‑pill instructions.

While the MHRA has identified the two faulty batches, it has not disclosed how many tablets were distributed before the error was caught, nor the exact timeline of the packaging mistake. It is also unclear whether any adverse events have been formally linked to the mis‑labelled leaflets, as the agency’s statement focuses on preventive advice rather than reported incidents.